BACARDI-LIMITED
Bacardi Limited, the largest privately held spirits company in the world, today announces moves within its global marketing leadership. John Burke, Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited, will retire after more than 28 years with the company at the end of 2022. During his tenure, he led many of the company’s leading brands, including most recently BACARDÍ® rum, BOMBAY SAPPHIRE® gin, MARTINI® vermouths and sparkling wines, and DEWAR’S® Blended Scotch whisky.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220916005301/en/
Ned Duggan will be promoted to Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited. (Photo: Business Wire)
“John is an incredibly strategic marketer who has helped us reinvigorate many brands and keep consumer at the heart of everything that we do. He played an important role in creating a disciplined marketing organization focused on building capabilities and driving brand equity over the years,” says Mahesh Madhavan, Chief Executive Officer of Bacardi Limited. “Under his leadership, we have seen many magical moments for our brands. He leaves us having imprinted his mark in our story – and a legacy he can be very proud of.”
“I am incredibly grateful for the many opportunities I have been given in my lifetime at Bacardi. I have had the opportunity to work with and learn from some remarkable people, and I hope I have been able to help them in return. I have loved nurturing our brands to make them stronger and see them grow,” says John Burke. “I am very proud of what we have achieved together and wish Bacardi good fortune and continued success for the future.”
Following John’s retirement, Ned Duggan will be promoted to Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited. Since 2017, Ned has led BACARDÍ® rum, first in market execution in North America and later globally from Bermuda as SVP. In addition to his continued leadership of BACARDÍ rum, he will add MARTINI®, DEWAR’S®, WILLIAM LAWSON’S®, D’USSÉ® Cognac, among others. Ned’s ascension is the culmination of a 17-year-tenure at Bacardi that began as an Assistant Brand Manager. His career has spanned assignments at regional and global levels working on many company brands, including DEWAR’S®, GREY GOOSE®, BOMBAY SAPPHIRE®, OXLEY®, ST-GERMAIN®, D’USSÉ®, and others. Ned, who will relocate to London, will report to CEO Mahesh Madhavan and joins the Global Leadership Team (GLT).
“I am incredibly honored and humbled to assume the role of CMO at Bacardi,” says Ned Duggan. “I have spent my career at this company, learning from the best and I am thrilled to enter this next phase of my journey working to further develop and grow our renowned portfolio.”
Kathy Parker, President & CMO of GREY GOOSE® vodka and the tequila portfolio, which includes PATRÓN® and CAZADORES®, will add BOMBAY SAPPHIRE® gin to her remit following John’s retirement. Kathy is a member of the company’s Global Leadership Team and reports to CEO Mahesh Madhavan.
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005301/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom